Neuropsychiatry Program, Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Harquail Centre for Neuromodulation and Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Can J Neurol Sci. 2023 Jun;50(s1):s34-s41. doi: 10.1017/cjn.2023.24. Epub 2023 May 10.
Placebo-controlled trials are the gold standard of evaluating treatment efficacy in clinical research. Neuromodulation is emerging as an important treatment pathway for many neuropsychiatric conditions, and placebo control arms of these trials require careful design with unique considerations (e.g., sham devices that mimic active stimulation, blinding effectiveness). Inherent to placebo-controlled trials are ethical concerns, such as deception, and potential harm of not receiving the active treatment. In this article, we outline important ethical considerations of placebo-controlled trials across neuromodulation approaches and provide recommendations on how ethical principles can be adhered to going forward. We specifically address issues of autonomy and respect for persons, beneficence, and justice. Within the context of this ethical framework, we also discuss factors influencing placebo effects in neuromodulation, the importance of adequate blinding, and alternative trial designs that could be considered.
安慰剂对照试验是评估临床研究治疗效果的金标准。神经调节作为许多神经精神疾病的重要治疗途径正在出现,这些试验的安慰剂对照臂需要精心设计并考虑独特的因素(例如,模仿主动刺激的假设备,盲法效果)。安慰剂对照试验固有的伦理问题,例如欺骗和不接受主动治疗的潜在危害。在本文中,我们概述了神经调节方法中安慰剂对照试验的重要伦理考虑,并就如何遵守伦理原则提出了建议。我们特别解决了自主性和尊重个人、善行和正义的问题。在这个伦理框架内,我们还讨论了影响神经调节中安慰剂效应的因素、充分盲法的重要性以及可以考虑的替代试验设计。